Journal article
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
D Yeo, H He, O Patel, AM Lowy, GS Baldwin, M Nikfarjam
BMC Cancer | BMC | Published : 2016
Abstract
Background: Pancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cancer, its role has not been fully elucidated. This study aimed to characterise the expression and functional relevance of PAK1 in pancreatic cancer. Methods: PAK1 expression was measured in pancreatic cancer specimens by immunohistochemistry and in pancreatic cancer cell lines by western blotting. The effect of inhibition of PAK1 by either shRNA knock-down (KD), or by a selective inhibitor, FRAX597, ..
View full abstractGrants
Awarded by National Science Foundation
Funding Acknowledgements
[ "We thank Prof. Ian Gordon, Statistical Consulting Centre, The University of Melbourne, Parkville, Australia for his assistance with statistical analysis, and Chelsea Dumesny, Nhi Huynh, and Marie Laval for skilled assistance with the animal experiments. D.Y. is supported by Australian Rotary Health (The Ian Loxton Pancreatic Cancer Research PhD Scholarship).", "This work was supported by National Health and Medical Research Council of Australia Grants [508908 to H.H] and [1020983 to G.S.B]; National Institutes of Health [CA155620-01 to A.M.L]; Austin Hospital Medical Research Foundation (M.N); and Sir Edward Dunlop Foundation Grant (M.N)." ]